Not a good buy right now for an impatient entry: price (~12.73 pre-market) is pressing near resistance (R1 12.863) while the longer-term trend remains bearish.
Short-term momentum is improving (positive, expanding MACD), but RSI is hot (~71), increasing the odds of a near-term fade rather than an immediate clean breakout.
Options positioning is call-heavy (bullish skew), but there is effectively no volume today—sentiment signal is weak.
With no proprietary buy signals today and no near-term news catalysts, the risk/reward favors waiting for a pullback closer to ~12.41 (pivot) or ~11.95 (S1) rather than buying into resistance.
Cons: still unprofitable, margin compression, and limited visibility/catalyst support implied by the lack of updates/news.
Politicians/influential figures: No recent politician/congress trading data available for the past 90 days.
Wall Street analysts forecast BOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOC is 20 USD with a low forecast of 20 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOC is 20 USD with a low forecast of 20 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.510
Low
20
Averages
20
High
20
Current: 12.510
Low
20
Averages
20
High
20
TD Cowen
Buy
downgrade
$25 -> $22
AI Analysis
2025-08-20
Reason
TD Cowen
Price Target
$25 -> $22
AI Analysis
2025-08-20
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Boston Omaha to $22 from $25 and keeps a Buy rating on the shares. The firm said Boston Omaha's 2Q results fell short of expectations, with insurance weighed down by a higher loss ratio and reserve additions as a percentage of earned premium. They reduced 2H billboard and insurance estimates.
